NM
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications |  | 2024 | 24 | 19 | ||
| Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy : a phase 2 multicentre study | BMJ open | | 2024 | 21 | 1 | ||
| ONE SHOT - single shot radiotherapy for localized prostate cancer : 18-month results of a single arm, multicenter phase I/II trial | Radiotherapy and oncology | | 2024 | 13 | 6 | ||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | 2023 | 11 | 6 | ||
| Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins | iScience | | 2023 | 43 | 13 | ||
| Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity | BMJ open | | 2023 | 291 | 37 | ||
| PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : Acute Toxicity of a Randomized Phase 2 Trial | European urology oncology |  | 2023 | 38 | 0 | ||
| The Future of Cancer Immunotherapy | Praxis | | 2023 | 53 | 2 | ||
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence | Oral oncology | | 2023 | 58 | 5 | ||
| Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model | AACR Annual Meeting 2023 | | 2023 | 21 | 11 | ||
| Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17 | Journal of clinical oncology | | 2023 | 32 | 38 | ||
| Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13) | EClinicalMedicine | | 2023 | 46 | 13 | ||
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | | 2023 | 43 | 15 | ||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | 2022 | 29 | 10 | ||
| Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA) | Cancers | | 2022 | 63 | 50 | ||
| Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study | Lung cancer | | 2022 | 139 | 49 | ||
| 1454P Optimizing ipilimumab in RCC : Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC | ESMO Congress 2022 | | 2022 | 36 | 15 | ||
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | 2022 | 140 | 56 | ||
| SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma | Blood advances | | 2022 | 64 | 206 | ||
| LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial | ESMO Congress 2022 | | 2022 | 41 | 18 | ||
| 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040 | European Society for Medical Oncology (ESMO) Congress | 2022 | 34 | 0 | |||
| Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology | Molecular therapy. Methods & clinical development | | 2022 | 94 | 32 | ||
| Local sustained GM-CSF delivery by genetically engineered encapsulated cells enhanced both cellular and humoral SARS-CoV-2 spike-specific immune response in an experimental murine spike DNA vaccination model | Vaccines | | 2021 | 159 | 104 | ||
| A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein | Vaccines | | 2021 | 217 | 64 | ||
| SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial | Journal of Clinical Oncology | | 2021 | 166 | 0 | ||
| Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors | Clinical Cancer Research | | 2021 | 141 | 1 | ||
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | | 2021 | 196 | 143 | ||
| Primary extra-osseous ewing sarcoma of the thyroid: a case report and review of the literature | Head and Neck Pathology | | 2021 | 198 | 103 | ||
| Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040 | Journal of the National Cancer Institute | | 2021 | 139 | 0 | ||
| Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study | Clinical Cancer Research | | 2020 | 127 | 0 | ||
| Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice | Schweizerische medizinische Wochenschrift | | 2020 | 133 | 18 | ||
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study | The Lancet | | 2019 | 143 | 0 | ||
| Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) | British Journal of Cancer | | 2019 | 136 | 54 | ||
| Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01) | Journal of Thoracic Oncology | | 2019 | 123 | 54 | ||
| Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy | Blood | | 2019 | 41 | 33 | ||
| Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma | Blood | | 2018 | 102 | 0 | ||
| Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial | Oral oncology | | 2018 | 35 | 0 | ||
| First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies | OncoImmunology | | 2017 | 569 | 9 | ||
| Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial | Clinical lung cancer | | 2017 | 465 | 1 | ||
| A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors | Cancer chemotherapy and pharmacology | | 2017 | 36 | 0 | ||
| Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers | Cancer immunology research | | 2016 | 35 | 0 | ||
| 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial | Journal of thoracic oncology | | 2016 | 464 | 135 | ||
| Giant Cell Tumor of Bone With Pseudosarcomatous Changes Leading to Premature Denosumab Therapy Interruption: A Case Report With Review of the Literature | International journal of surgical pathology | 2016 | 497 | 0 | |||
| Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08 | British journal of haematology | | 2016 | 36 | 0 | ||
| Comparison of the incidence of osteoradionecrosis with conventional radiotherapy and intensity-modulated radiotherapy | Head & neck | | 2016 | 555 | 1 | ||
| Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system | International journal of molecular sciences | | 2015 | 152 | 74 | ||
| Traitement des carcinomes épidermoïdes ORL chez la personne âgée | Revue médicale suisse | | 2015 | 426 | 0 | ||
| Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation : Phase II Trial SAKK19/09 | Clinical lung cancer | | 2015 | 31 | 0 | ||
| Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma | British journal of cancer | | 2014 | 502 | 133 | ||
| Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial | The lancet oncology | | 2014 | 102 | 0 | ||
| Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors | Cancer immunology and immunotherapy | | 2014 | 84 | 0 | ||
| Chirurgie du cancer pulmonaire à petites cellules de stade précoce: doit-on réévaluer son rôle? | Revue médicale suisse | | 2013 | 94 | 68 | ||
| Cancers liés au HPV: faut-il vacciner les jeunes hommes? | Revue médicale suisse | | 2012 | 160 | 55 | ||
| Role of the cytokine GM-CSF in cell-based anti-tumor immunity: learning from murine models to engineer new therapeutic strategies | | 2012 | 689 | 813 | |||
| Le cancer du poumon chez la femme est-il différent? | Revue médicale suisse | | 2012 | 103 | 84 | ||
| Thérapies ciblées du cancer pulmonaire: tests moléculaires à partir d'échantillons cytologiques | Revue médicale suisse | | 2011 | 570 | 3 | ||
| Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy | Cancer gene therapy | | 2011 | 758 | 0 | ||
| Anticancéreux sous haute tension | Revue médicale suisse | | 2011 | 505 | 1 | ||
| Role of GM-CSF signaling in cell-based tumor immunization | Blood | | 2009 | 736 | 2 | ||
| Is there a place for low-dose chest and prophylactic brain irradiation in limited-disease small cell lung cancer | Medical oncology | | 2009 | 545 | 0 | ||
| Intravenous leiomyomatosis of the uterus: link with new fertilisation methods? | Schweizerische medizinische Wochenschrift | | 2009 | 543 | 303 | ||
| Intestinal colonization of IL-2 deficient mice with non-colitogenic B. vulgatus prevents DC maturation and T-Cell polarization | PloS one | | 2008 | 78 | 24 | ||
| Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 | Annals of oncology | | 2008 | 115 | 45 | ||
| CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine | Proceedings of the National Academy of Sciences of the United States of America | | 2007 | 77 | 0 | ||
| Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer | The cancer journal | | 2006 | 623 | 467 | ||
| Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process | International journal for quality in health care | | 2006 | 39 | 0 | ||
| Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience | International journal of radiation oncology, biology, physics | | 2004 | 545 | 489 | ||
| Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy | Head & neck | | 2003 | 594 | 1 290 | ||
| CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion | Proceedings of the National Academy of Sciences of the United States of America | | 2003 | 34 | 6 | ||
| In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury | American journal of physiology. Lung cellular and molecular physiology | | 2002 | 46 | 0 | ||
| Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation | Cancer research | | 2001 | 37 | 0 | ||
| Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity | Blood | | 2001 | 20 | 6 | ||
| Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand | Cancer research | | 2000 | 29 | 0 | ||
| Cytokine-secreting tumor cell vaccines | Current opinion in immunology | | 2000 | 35 | 0 | ||
| Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites | Nature | | 1998 | 62 | 0 | ||
| Involvement of interleukin-3 in delayed-type hypersensitivity | Blood | | 1998 | 29 | 2 | ||
| Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome | The New England journal of medicine | | 1990 | 537 | 99 |
